Latest Period
Q2 2026
Security Snapshot
Prime Medicine, Inc. - COMMON STOCK (PRME) Institutional Ownership
CUSIP: 74168J101
13F Institutional Holders and Ownership History from Q4 2022 to Q2 2026
Institutions Reporting
186
Shares (Excl. Options)
106,647,871
Price
$3.69
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- PRME on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 106,647,871
- Total 13F value
- $393,491,922
- Portfolio coverage rank
- 0%
- Share change
- +8,090,362
- Value change
- +$29,961,767
- Number of holders
- 186
- Shares outstanding
- 181,672,212
- SEC-reported price per share
- $3.03
- Insider filing price
- $3.03
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PRME - Prime Medicine, Inc. - COMMON STOCK is tracked under CUSIP 74168J101.
- 186 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 190 to 186 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $342,542,221 to $393,491,922.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 186 institutions filings for Q2 2026.
Security key
74168J101
Latest holder period
Q2 2026
13F holders
186
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
PRME full holder history
Prime Medicine, Inc. SEC filings
Prime Medicine, Inc. company facts
Prime Medicine, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74168J101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PRME
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 10% | $80,853,607 | 18,587,036 | Robert Nelsen | 07 Aug 2025 | |||
| GV 2019, L.P. | 12% | $91,756,239 | 16,562,498 | Alphabet Holdings LLC | 30 Sep 2025 | |||
| FMR LLC | 3.8% | $37,294,150 | 6,731,796 | FMR LLC | 30 Sep 2025 | |||
| Newpath Partners, L.P. | 4.7% | $9,769,086 | 6,105,679 | Newpath Partners, L.P. | 31 Dec 2024 | |||
| T. Rowe Price Investment Management, Inc. | 3.3% | -40% | $25,659,383 | -$13,874,784 | 5,995,183 | -35% | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 |
As of 30 Jun 2026, 186 institutional investors reported holding 106,647,871 shares of Prime Medicine, Inc. - COMMON STOCK (PRME). This represents 59% of the company’s total 181,672,212 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
50%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Alphabet Inc. | 9.1% | 16,562,498 | 0% | 0.06% | $61,115,618 |
| BlackRock, Inc. | 5.3% | 9,602,041 | +13% | 0% | $35,431,531 |
| ARK Investment Management LLC | 4.6% | 8,348,746 | +34% | 0.2% | $30,806,875 |
| STATE STREET CORP | 4.2% | 7,576,460 | +19% | 0% | $27,957,137 |
| T. Rowe Price Investment Management, Inc. | 2.9% | 5,237,332 | -4.5% | 0.01% | $19,326,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 4,522,640 | +1.1% | 0% | $16,688,542 |
| Balyasny Asset Management L.P. | 2.2% | 3,969,082 | -3.7% | 0.03% | $14,645,913 |
| GOLDMAN SACHS GROUP INC | 1.9% | 3,430,518 | +254% | 0% | $12,658,612 |
| Casdin Capital, LLC | 1.7% | 3,167,175 | 0% | 0.58% | $11,686,876 |
| Woodline Partners LP | 1.7% | 3,003,904 | +0.02% | 0.03% | $11,084,406 |
| UBS Group AG | 1.5% | 2,794,689 | -3.2% | 0% | $10,312,403 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 2,712,446 | -1.1% | 0% | $10,011,771 |
| Sumitomo Mitsui Trust Group, Inc. | 1.3% | 2,412,984 | -18% | 0.01% | $8,903,911 |
| Amova Asset Management Americas, Inc. | 1.3% | 2,407,018 | -18% | 0.11% | $8,857,826 |
| CITADEL ADVISORS LLC | 1.1% | 2,054,543 | +511% | 0% | $7,581,264 |
| ADAR1 Capital Management, LLC | 1.1% | 1,997,552 | +1.2% | 0.35% | $7,370,967 |
| FMR LLC | 0.97% | 1,761,884 | -0.43% | 0% | $6,501,352 |
| TWO SIGMA INVESTMENTS, LP | 0.84% | 1,524,511 | -3.1% | 0% | $5,625,446 |
| Redmile Group, LLC | 0.76% | 1,389,632 | -13% | 0.34% | $5,127,742 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 0.68% | 1,240,843 | 0% | 0.03% | $4,578,711 |
| Jump Financial, LLC | 0.68% | 1,240,429 | 0.04% | $4,577,183 | |
| BANK OF AMERICA CORP /DE/ | 0.54% | 981,335 | +70% | 0% | $3,621,126 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.53% | 961,826 | +12% | 0% | $3,549,138 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.51% | 927,538 | +1.1% | 0% | $3,422,615 |
| NORTHERN TRUST CORP | 0.5% | 912,597 | +2.9% | 0% | $3,367,482 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Latest
Q2 2026
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 106,647,871 | $393,491,922 | +$29,961,767 | $3.69 | 186 |
| 2026 Q1 | 98,524,485 | $342,542,221 | +$12,476,321 | $3.48 | 190 |
| 2025 Q4 | 97,023,958 | $336,615,184 | +$756,626 | $3.47 | 183 |
| 2025 Q3 | 92,347,818 | $511,536,971 | +$186,859,809 | $5.54 | 165 |
| 2025 Q2 | 58,654,950 | $144,864,309 | -$2,708,584 | $2.47 | 118 |
| 2025 Q1 | 60,327,480 | $120,048,763 | -$9,144,075 | $1.99 | 121 |
| 2024 Q4 | 64,302,617 | $187,767,212 | -$16,411,951 | $2.92 | 128 |
| 2024 Q3 | 68,711,037 | $265,862,243 | -$1,687,770 | $3.87 | 113 |
| 2024 Q2 | 68,888,470 | $353,995,003 | +$8,574,594 | $5.14 | 119 |
| 2024 Q1 | 66,659,039 | $466,578,147 | +$125,445,462 | $7.00 | 112 |
| 2023 Q4 | 48,691,116 | $431,437,073 | -$10,408,984 | $8.86 | 102 |
| 2023 Q3 | 49,517,421 | $472,282,828 | +$28,502,950 | $9.54 | 82 |
| 2023 Q2 | 46,131,758 | $675,732,293 | +$67,078,075 | $14.65 | 77 |
| 2023 Q1 | 41,738,575 | $512,085,492 | +$2,897,210 | $12.30 | 73 |
| 2022 Q4 | 41,322,385 | $767,784,036 | +$767,085,261 | $18.58 | 65 |